Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment. In addition, the immune environment surrounding the tumor changes significantly during the course of the disease, and the body's immun
| Condition(s) | Localized Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment. In addition, the immune environment surrounding the tumor changes significantly during the course of the disease, and the body's immune response to cancer tends to become less effective in later stages. Currently, standard blood tests provide only basic information about a patient's immune, inflammatory, and metabolic systems. These tests do not offer a comprehensive picture of how each person's immune system is functioning. Similarly, traditional tests on tumor samples-which require frozen or preserved tissue and take a long time to process-are not fast enough to guide treatment decisions during clinical t |
| Who can participate | Inclusion Criteria: 1. Ageā„ 12 years with at least 40kg body weight or otherwise as per specified in sub-protocol. 2. Prior to the inclusion in the NEOREM master protocol, patients must have signed a written informed consent to baseline PORTRAIT profiling. Note: * When the patient is physically unable to give his/her written consent, a trusted person of his/her choice, independent from the investigator or the sponsor, can confirm in signing the patient's consent. * For patients aged between \> 12 and \< 18, specific consent from legal tutors should be obtained on top of the minor consent and prior procedures. 3. Localized solid malignancy that is eligible to receive neo-adjuvant therapy and has medical unmet needs related to disease-free survival, overall survival or quality of life. Note: |
| Ages | 12 Years |
| Sex | All |
| Lead sponsor | UNICANCER |
| Locations | Villejuif, France |
| Start date | 2026-01-21 |
| NCT ID | NCT07262489 |
| Official listing | https://clinicaltrials.gov/study/NCT07262489 |